- $81.77m
- -$87.65m
- CNY807.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.56 | ||
| Price to Tang. Book | 0.57 | ||
| Price to Free Cashflow | 11.97 | ||
| Price to Sales | 0.69 | ||
| EV to EBITDA | -7.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.65% | ||
| Return on Equity | 9.75% | ||
| Operating Margin | 8.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 944.72 | 985.52 | 1,018.14 | 922.2 | 807.02 | n/a | n/a | 8.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +62.59 | -44.99 | -1.94 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
iHuman Inc is a holding company primarily engaged in the provision of tech-powered, intellectual development products for children. The products primarily include interactive and self-directed apps, offline products and others, as well as animated content and derivative offerings. The interactive and self-directed apps are offered under the brands iHuman bekids and Aha World. The apps primarily include iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHumanpedia, bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, Aha World and Aha Makeover. The Company is also engaged in the development of stimulating materials, including books, interactive materials and smart devices for children. The Company operates its businesses in the domestic market and overseas markets.
Directors
- Yufeng Chi CHM (50)
- Peng Dai CEO (41)
- Weiwei Wang CFO (43)
- Wenbin Lu CTO
- Hanfeng Chi DRC (54)
- Wendy Hayes IND (51)
- Xuenan Li IND
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- September 28th, 2019
- Public Since
- October 9th, 2020
- No. of Employees
- 558
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
New York Stock Exchange- Shares in Issue
- 255,541,887
- Address
- Floor 8, Building 2,, No.1 Wangjing, BEIJING, 100102
- Web
- https://www.ihuman.com/
- Phone
- +86 1057806636
- Contact
- Justin Zhang
- Auditors
- Ernst & Young Hua Ming LLP
Upcoming Events for IH
Similar to IH
A10 Networks
New York Stock Exchange
Accelerant Holdings
New York Stock Exchange
Accenture
New York Stock Exchange
ACV Auctions
New York Stock Exchange
Alibaba Holding
New York Stock Exchange
FAQ
As of Today at 12:15 UTC, shares in Ihuman are trading at $1.60. This share price information is delayed by 15 minutes.
Shares in Ihuman last closed at $1.60 and the price had moved by -26.31% over the past 365 days. In terms of relative price strength the Ihuman share price has underperformed the S&P500 Index by -42.78% over the past year.
The overall consensus recommendation for Ihuman is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIhuman does not currently pay a dividend.
Ihuman does not currently pay a dividend.
Ihuman does not currently pay a dividend.
To buy shares in Ihuman you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.60, shares in Ihuman had a market capitalisation of $81.77m.
Here are the trading details for Ihuman:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: IH
Based on an overall assessment of its quality, value and momentum Ihuman is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ihuman is $4.08. That is 155.08% above the last closing price of $1.60.
Analysts covering Ihuman currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ihuman. Over the past six months, its share price has underperformed the S&P500 Index by -46.21%.
As of the last closing price of $1.60, shares in Ihuman were trading -25.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ihuman PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ihuman's management team is headed by:
- Yufeng Chi - CHM
- Peng Dai - CEO
- Weiwei Wang - CFO
- Wenbin Lu - CTO
- Hanfeng Chi - DRC
- Wendy Hayes - IND
- Xuenan Li - IND